• CVS Health-backed CVS Caremark survey flagged employer focus on rising drug prices, specialty access, biosimilars, GLP-1 spending.
• 91% of employers reported concern over high medication prices for employees; 88% viewed PBMs as well positioned to cut costs.
• Only 49% encouraged biosimilar substitution; 40% considered it; 12% educated employees on potential savings.
• CVS Caremark reported over USD 3.3 billion in gross Humira-related savings since April 2024 from biosimilar formulary strategy.
• 77% cited GLP-1 coverage costs as a concern; 80% limited weight-loss GLP-1 coverage or considered limits.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CVS Health Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608120900PR_NEWS_USPR_____NE24044) on August 12, 2026, and is solely responsible for the information contained therein.